New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD

Core Insights - The Phase 3 PRECISION trial analysis demonstrates the renal-protective benefits of aprocitentan alongside significant blood pressure reduction in high-risk chronic kidney disease (CKD) patients with resistant hypertension [1][2][3] Company Overview - Idorsia Ltd, headquartered in Allschwil, Switzerland, focuses on developing transformative medicines, including aprocitentan, which targets the endothelin pathway for treating systemic hypertension and resistant hypertension [2][10][22] Clinical Study Findings - The PRECISION study involved 730 patients with confirmed resistant hypertension, with a specific focus on 147 participants with CKD categorized as high or very high risk according to KDIGO criteria [9][11] - Aprocitentan significantly reduced office systolic blood pressure (SBP) by -15.3 mmHg and -15.2 mmHg for the 12.5 mg and 25 mg doses, respectively, compared to -11.5 mmHg for placebo [13] - Nighttime ambulatory SBP was reduced by -9.6 mmHg and -13.8 mmHg for the 12.5 mg and 25 mg doses, respectively, versus -2.5 mmHg with placebo [14] - Aprocitentan also lowered urinary albumin-to-creatinine ratio (UACR) by -47.1% and -59.6% for the respective doses, indicating a significant antiproteinuric effect [14] Safety and Tolerability - Aprocitentan was well tolerated, with the most common adverse event being mild-to-moderate peripheral edema, manageable with diuretic adjustments [3][16] - No significant changes in potassium levels or estimated glomerular filtration rate (eGFR) were observed, indicating a favorable safety profile [14][16] Market Context - Approximately 1.4 billion people globally suffer from hypertension, which remains a leading health challenge and a major risk factor for cardiovascular diseases [5][6] - In the US, around 50% of patients with hypertension on multiple treatments do not achieve blood pressure control, highlighting the need for effective therapies like aprocitentan [5][6]